Other Events ·
Stockholders approve reverse split authority between 1-for-10 and 1-for-50
ATYRaTYR PHARMA Inc
At its Special Meeting on October 16, 2026, aTyr Pharma stockholders approved Proposal 1 by a vote of approximately 90.5% in favor. The proposal grants the Board of Directors authority to effect a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-50, with the specific ratio to be determined at the Board's discretion. This action is intended to help the company maintain compliance with Nasdaq listing requirements. aTyr Pharma Inc. operates as a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.